Stay updated on Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov site revision identifier was updated to v3.8.1.
    Difference
    0.0%
    Check dated 2026-11-18T01:38:46.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page displays the completed phase 2 pembrolizumab study record, including its design, eligibility criteria, locations, outcomes, publications, and record dates.
    Difference
    77%
    Check dated 2026-11-10T22:55:12.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.8.0 instead of v3.7.2. The page still shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T22:57:33.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    A new NIH transition notice appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The clinical trial record itself remains inaccessible behind a 403 error.
    Difference
    1%
    Check dated 2026-10-20T22:09:28.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T22:21:13.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error for the study record, replacing the previous detailed content. Sponsor-related materials and links to study documents have been removed.
    Difference
    18%
    Check dated 2026-09-23T00:10:28.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.